5F-AMB


5F-AMB is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in early 2014.
Although only very little pharmacological information about 5F-AMB itself exists, its 4-cyanobutyl analogue has been reported to be a potent agonist for the CB1 receptor.

Side effects

5F-AMB intoxication caused one fatality on its own and another one through ketoacidosis in combination with AB-CHMINACA, AB-FUBINACA, AM-2201, 5F-APINACA, EAM-2201, JWH-018, JWH-122, MAM-2201, STS-135 and THJ-2201 and another fatality in combination with AB-CHMINACA and Diphenidine.

Legality

In the United States, 5F-AMB is a Schedule I controlled substance.
5F-AMB is an Anlage II controlled substance in Germany as of May 2015.
Sweden's public health agency suggested classifying 5F-AMB as hazardous substance on November 10, 2014.
The state of Louisiana banned 5F-AMB through an emergency rule after it was detected in a synthetic cannabinoids product called "Kali Berry 2" on 3 June 2014.
5F-AMB is controlled by the Fifth Schedule of the Misuse of Drugs Act in Singapore as of May 2015.
5F-AMB was also scheduled in Japan on July 25, 2014.
As of October 2015 5F-AMB is a controlled substance in China.
In December of 2019, the UNODC announced scheduling recommendations placing 5F-MMB-PINACA into Schedule II.